ftInvstr
SANOFICONR · Healthcare ₹4185.0 +0.0% Mkt Cap ₹9681 Cr overvalued

SANOFICONR

Healthcare Drug Manufacturers - General
₹4185.0
+0.0% today · 30d -7.53%
as of 2026-09-04
Price · Daily Candles
“Sanofi India: Strong Q1 profit growth overshadowed by volatile share price and FII retreat.”
Sanofi India posted impressive headline growth in Q1 2026, with net profit up 35.6% YoY to ₹68 Cr on a 32.79% revenue increase. Despite an attractive dividend yield of 1.16%, its current PE of 41.56, coupled with a 9.35% price decline over the last year, hints at investor caution. Analyst coverage remains thin, with only one analyst providing a target of ₹5855.
BULL CASE
+Q1 2026 revenue surged 32.79% YoY to ₹229 Cr, while net profit grew 35.6% YoY to ₹68 Cr.
+Operating profit increased 36.42% YoY to ₹94 Cr in Q1 2026, with OPM improving by 1.28 percentage points.
+The company maintains a high level of promoter holding at 71.27% as of March 2026.
+DII holding increased by 0.24% QoQ to 17.57% in Q1 2026, indicating domestic institutional confidence.
+The profitability score is 'HIGH' at 100, reflecting strong operational efficiency.
BEAR CASE
The stock price has fallen 9.35% over the past year and remains 21.27% off its 52-week high of ₹5894.5.
FIIs reduced their stake by 0.07% QoQ in Q1 2026, bringing their total holding to 2.76%.
The PE ratio of 41.56 is higher than peers like PFIZER (29.39) and MARKSANS (30.34).
The ML model indicates weak growth potential for Free Cash Flow (FCF) in the near term, with a rank of 0.255 for recent 2-year FCF growth.
Technical indicators like MACD and RSI(14) are currently neutral, with RSI showing a weak signal at 47.74.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹236 Cr
+6.7% YoY
NET PROFIT
₹69 Cr
+13.34% YoY
OPM
39.5%
+6.04pp YoY
EPS
₹29.87
PE 41.56
Intrinsic value · DCF ₹539.10 · Margin of safety -87.1% (overvalued) · FCF yield 1.73%
◇ Sector Position
Sanofi India, with a PE of 41.56, trades at a premium to peers like Pfizer (PE 29.39) and Marksans (PE 30.34), but offers a competitive ROCE compared to Rubicon (ROCE 40.26) and Corona (ROCE 35.68).
PEERPEROCE %
SANOFICONR41.56
GLAXO37.3260.28
PFIZER29.3925.0
RUBICON119.8940.26
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
56
SCORE / 100
Overall
6-axis composite of the sections below.
Performance UNDERPERFORMER 20
Valuation FAIR 40
Growth STEADY 52
Profitability HIGH 95
Technicals WEAK 40
Risk LOW 88
Key Stats
TTM PE
41.56
P/B
27.92
52W HIGH
₹5357.0
OFF HIGH
-21.88%
DIV YIELD
1.16%
MKT CAP
₹9681 Cr
◉ Active Signals
MACDNeutral4.5593
RSI(14)Bearish35.88
Near 52W LowBearish5.28
Street Consensus
1 analyst
₹5855.0
mean target
Low ₹5855.0Now ₹4185.0High ₹5855.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold SANOFICONR and at what entry.

Sign up freeSign in